Retatrutide is a novel triple receptor agonist (GLP-1, GIP, and glucagon receptor) currently under Phase III clinical investigation for metabolic research applications
Interested in Starting a GLP-1 Program
24 to 48 hours)
BOMSS recommends a comprehensive blood monitoring panel that typically includes full blood count, urea and electrolytes, liver function tests, ferritin, folate, vitamin B12, vitamin D, calcium, and parathyroid hormone (PTH)
Third-party testing from ISO 17025 accredited laboratories provides unbiased quality data
Rybelsus is FDA-approved for type 2 diabetes and for reducing the risk of serious cardiovascular problems in people with type 2 diabetes